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Abstract 
 20 
In vivo biodistribution of nanoparticles depends on several physicochemical parameters such as 
size. After intravenous injection of 25, 50 and 100 nm lipid nanocapsules (LNC) in nude mice 
bearing HEK293(β3) tumour xenografts, biodistribution was evaluated by γ-scintigraphy and by γ-
counting. The small LNC 25 nm disappeared faster than the larger LNC 50 and 100 nm from the 
blood circulation due to faster elimination and wider tissue distribution. At 24 h, biodistribution 25 
profiles of all these LNC were similar. Low LNC quantities were found in this weak EPR 
(enhanced permeability and retention) tumour regardless the particle size. Co-injected 50 nm 
fluorescent DiD-LNC and 
99m
Tc-LNC allowed direct comparison of biodistribution as evaluated by 
the two methods. Optical imaging underestimated LNC quantity especially in dark-coloured organs 
that were observed to capture extensive quantities of the particles by γ-counting (i.e. liver, spleen, 30 
and kidney). 
 
Keywords: lipid nanocapsules, biodistribution, γ-scintigraphy, optical imaging, fluorescence 
 3 
1 Introduction 35 
 
Extensive studying of nanoparticles during the last decades has resulted in drug delivery systems 
that protect the active substance, improve solubility and carry the drug to specific tissues in the 
body (Farokhzad and Langer, 2009). Cancer therapy is one of the areas that benefit considerably 
from these advances (Hirsjärvi et al., 2011). In order to develop an efficient nanoparticulate drug 40 
delivery system, its pharmacokinetic profile as well as biodistribution should be evaluated when the 
system is transferred from in vitro assays to first preclinical tests. Molecular imaging offers tools for 
non-invasive evaluation (Baker, 2010), and the same probes used also allow tissue distribution 
determination after animal sacrifice. Commonly used small animal imaging technologies include X-
ray computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography 45 
(PET), single photon emission computed tomography (SPECT) and different optical imaging 
techniques (Dufort et al., 2010). Optical imaging techniques are sensitive, non-ionizing, fast and 
easy to perform, portative and cheap. However, quantitative performance of optical techniques still 
needs improvement in order to overcome the problems of absorption and autofluorescence. SPECT 
can overcome optical imaging problems because it provides more reliable quantitative information 50 
about physiological functions at the molecular level and it is, thus, well suited for monitoring many 
vital processes such as blood flow and perfusion, receptor-ligand binding rates, and oxygen 
utilization. SPECT has no depth limit but the acquisition times might be from several minutes up to 
hours. However, SPECT suffers from some noteworthy other disadvantages such as the need of 
radiolabelled particles, and adapted and expensive devices. Both SPECT and optical imaging 55 
possess a resolution of 1 mm (for more detail, please see (Dufort et al., 2010)). 
 
Biocompatible nanoparticles for drug delivery are usually made of polymer or lipid materials 
(Kumari et al., 2010; Müller et al., 2011; Torchilin, 2007; Torchilin, 2005). Lipid nanocapsules 
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(LNC) are synthetic particles having a hybrid structure between polymer nanoparticles and 60 
liposomes (Heurtault et al., 2002). LNC consist of low-toxicity materials (PEGylated surfactant, 
lecithin, triglycerides) and their fabrication, based on low-energy organic solvent-free phase 
inversion process, can be easily scaled up. By changing proportions of the components, the LNC 
size can be tuned within the range of 20-100 nm (Heurtault et al., 2003). LNC have been applied 
e.g. in the delivery of cancer therapeutics (Cirpanli et al., 2011; Garcion et al., 2006; Lacoeuille et 65 
al., 2007; Paillard et al., 2010; Peltier et al., 2006; Weyland et al., 2011) and other drug molecules 
(Lamprecht et al., 2004) as well as macromolecules such as siRNA and DNA (Morille et al., 2010; 
Morille et al., 2011). Because of their semi-rigid shell, LNC can be modified by post-inserting 
amphiphilic molecules. This kind of post-insertion allows for e.g. improvement of biodistribution 
profiles (Hoarau et al., 2004; Morille et al., 2010) or creation of templates for further attachment of 70 
active targeting ligands (Béduneau et al., 2008; Béduneau et al., 2007; Bourseau-Guilmain et al., 
2012). Radioactive molecules such as 
99m
Tc and 
188
Re have been successfully encapsulated in LNC 
as forms of lipophilic complexes (Ballot et al., 2006). These kinds of radio-labelled LNC can be 
used in biodistribution studies, imaging purposes and in radiotherapy (Allard et al., 2008; Ballot et 
al., 2006; Vanpouille-Box et al., 2011a; Vanpouille-Box et al., 2011b). 75 
 
In a previous study, we have evaluated the biodistribution profile of LNC of three different sizes 
(25, 50 and 100 nm) with the help of an optical imaging technique, fluorescence reflectance 
imaging (2D-FRI) (Hirsjärvi et al., 2013). Nude mice bearing subcutaneous HEK293(β3) (human 
embryonic kidney) xenografts were used in the study. Images taken at 1.5-3 h after intravenous 80 
injection revealed that fluorescence staining of the smallest LNC (25 nm) was more homogeneous 
throughout the mice than the staining of the bigger LNC: the 50 and 100 nm LNC were found 
mostly in the liver. However, when the mice were sacrificed after 24 h, tissue distribution profiles, 
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evaluated by fluorescence intensity, were similar for the three LNC sizes. With all three sizes, 
tumour could be distinguished from the images. 85 
 
In the present study, to get more quantitative information about LNC pharmacokinetics and 
biodistribution, 
99m
Tc-labelled LNC of the same three sizes (25, 50 and 100 nm) were injected 
intravenously in nude mice bearing the same tumour model (HEK293(β3) xenografts). γ-
Scintigraphy was performed at different time points up to 24 h together with tissue distribution 90 
determination by γ-counting at 1.5, 4 and 24 h. To compare the performance of 2D-FRI imaging 
(region of interest (ROI) drawing around each organ from the images taken with a fluorescence 
camera) and γ-counting in the determination of tissue distribution, mice were co-injected a mixture 
of fluorescence-labelled (DiD) and 
99m
Tc-labelled LNC of one chosen size (50 nm). 
 95 
2 Materials and Methods 
 
2.1 Materials 
 
Solutol® HS15 (PEG 660 12-hydroxystearate, MW ~ 870 Da) (BASF, Ludwigshafen, Germany), 100 
Labrafac™ WL 1349 (caprylic/capric acid triglycerides) (Gattefossé S.A., Saint-Priest, France), 
Lipoid® S75-3 (MW ~ 780 Da) (Lipoid GmbH, Ludwigshafen, Germany), NaCl (Prolabo VWR 
International, Fontenay-sous-Bois, France) and deionized MilliQ185 water (Waters, Saint-Quentin-
en-Yveline, France) were used in the LNC preparation. 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine perchlorate (DiD) was from Invitrogen (Cergy Pontoise, France). 105 
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2.2 Methods 
 110 
2.2.1 Preparation of the 
99m
Tc-SSS complex 
 
Pertechnetate (
99m
TcO4
-
) was obtained from the University Hospital of Angers (CHU Angers, 
France). The 
99m
Tc-SSS complex (bis (perthiobenzoato) (dithiobenzoato) technetium(III) 
heterocomplex) was prepared according to the following method (Ballot et al., 2006; Mévellec et 115 
al., 2002): 750 MBq of 
99m
TcO4
-
 in 0.5 mL 0.9% NaCl was added to a freeze-dried formulation kit 
containing 30 mg sodium gluconate, 30 mg ascorbic acid, 40 mg potassium oxalate, and 4 mg 
SnCl2·2H2O reconstituted in 0.5 mL 0.9% NaCl, and the solution was mixed for 15 minutes at room 
temperature. Then, 20 mg of sodium dithiobenzoate ligand (in 0.5 mL, pH 7) (Platform of Organic 
Synthesis, Rennes, France) was added and the mixture was heated at 100 °C for 30 minutes, which 120 
allowed formation of the 
99m
Tc-SSS complex. The complex was extracted with dichloromethane (1 
mL) and washed three times with 1 mL water. 
 
2.2.2 LNC preparation and characterization 
 125 
LNC were prepared by the phase inversion temperature method described by Heurtault et al. 
(Heurtault et al., 2003). Solutol®, Lipoid®, Labrafac®, NaCl and water were mixed and the 
99m
Tc-
SSS complex in dichloromethane (
99m
Tc-LNC) or DiD in acetone (DiD-LNC) was added to this 
mixture. When preparing fluorescent LNC, final concentration of DiD was 3 mmol/L / total 
Labrafac® amount. Dichloromethane/acetone was evaporated by heating at 60 °C for 15 min under 130 
stirring. The formulation was heated to 85 °C at a rate of 5 °C / min followed by cooling at the same 
rate to 65 °C. This cycle was repeated twice. During the last decrease of temperature, at 78 °C 
(during the phase inversion zone), the system was diluted with 4.2 mL cold (4 °C) water leading to 
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formation of stable LNC. Size of the LNC (25, 50, 100 nm) was adjusted by changing the 
proportions of the components (Table 1). 135 
 
Size distributions and zeta (ζ) potentials of LNC were determined with a Zetasizer ZS (Malvern, 
Worcestershire, UK). Particle sizing was based on photon correlation spectroscopy (PCS); the 
results were analyzed by CONTIN algorithm and the sizes were presented based on the volume 
distributions together with polydispersity indices (PdI). Electrophoretic mobilities were converted 140 
to ζ-potentials using Smoluchowski’s equation. 
 
2.2.3 Cells 
 
HEK293(β3) cells, stable transfectants of human β3 from the human embryonic kidney cell line 145 
(kindly provided by J.-F. Gourvest, Aventis, France), were cultured in DMEM supplemented with 
1% glutamine, 10% fetal bovine serum (FBS), 50 units/mL penicillin, 50 µg/mL streptomycin, and 
700 µg/mL Geneticin (G418 sulfate, Gibco, Paisley, UK), at 37 °C in a humidified 95% air / 5% 
CO2 atmosphere. 
 150 
2.2.4 In vivo imaging and biodistribution study 
 
The animal experiments were performed in agreement with the EU Directive 2010/63/EU for 
animal experiments, and the “Principles of Laboratory Animal Care” (NIH Publication no. 86-23, 
revised 1985), and the experimental protocol was approved by the local ethics committee. 155 
 
40 female NMRI nude mice (5 weeks old, JANVIER, Le Genest Saint Isle, France) were injected 
subcutaneously with HEK293(β3) cells (1×10
7
 / mouse). After tumor growth (~ 4 weeks), mice 
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were anesthetized with a mixture of ketamine (100 µg/g) / medetomidine (0.2 µg/g) by an 
intraperitoneal injection, and then 200 µL of LNC (about 100 mg/mL) were injected intravenously 160 
in the tail vein. Thus, each mouse obtained a dose of about 26 MBq 
99m
Tc (
99m
Tc-LNC). The mice 
which were injected by the mixture radio- and fluorescence-labelled LNC obtained 100 µL of 
99m
Tc-LNC (13 MBq) and 100 µL of DiD-LNC (same quantity of both LNC). 
 
In γ-scintigraphy, the injected mice were visualized under a clinical γ-camera (Sopha Medical 165 
DSXi, 140 keV±15%, 128
2
 matrix, HRLE collimator). Static 15 min scintigraphic images were 
registered at 1.5 h, 3 h, 5h, and 24 h (a video clip of dynamic 30 s scintigraphic acquisitions 
collected until 90 min post-injection is available as Supporting Content). To study tissue 
distribution of LNC, the animals were sacrificed at 1.5 h (n = 4), 4 h (n = 4), and 24 h (n = 4) after 
injection. The organs/tissues were removed, rinsed, and weighed. Activity of each removed organ 170 
was determined using a γ-counter (Packard Auto-Gamma 5,000 series). 
 
Fluorescent images were acquired by a back-thinned CCD camera at -80°C (ORCAII-BT-512G, 
Hamamatsu, Massy, France). Image display and analysis of the dissected organs were performed 
using the Wasabi software (Hamamastsu, Massy, France). Semi-quantitative data were obtained by 175 
drawing regions of interest (ROI) around each organ. The results of organ fluorescence 
quantifications were expressed as number of relative light units (RLU)/pixel. 
 
When imaging and quantifying the mice that obtained the mixture of radio- and fluorescence-
labelled LNC, fluorescence acquisitions were performed before scintigraphic acquisitions and γ-180 
counting. 
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2.2.5 Statistical analysis 
 185 
Biodistribution data was analyzed using one-way ANOVA with Tukey’s multiple comparison test 
(Prism, GraphPad Software, Inc., La Jolla, CA). p < 0.05 was considered as statistically significant. 
 
3 Results 
 190 
3.1 LNC preparation 
 
Size and ζ-potential of 99mTc-LNC are presented in Table 2. These characteristics of DiD-LNCs 
were identical with 
99m
Tc-LNC (Hirsjärvi et al., 2013). PdI-values of all three types of LNC were 
low indicating homogeneous size distributions. Slightly negative ζ-potential of LNC originates from 195 
PEG groups at the surface forming dipoles able to interact with counterions or water dipoles 
(Vonarbourg et al., 2005). Encapsulation of lipophilic 
99m
Tc or DiD in the oily core of LNC did 
change neither size nor ζ-potential of the blank LNC as reported earlier (Ballot et al., 2006; Morille 
et al., 2010; Paillard et al., 2010; Zou et al., 2008). 
 200 
3.2 In vivo biodistribution of 
99m
Tc-LNC 
 
Biodistribution of 25, 50, and 100 nm 
99m
Tc-LNC in different organs 1.5 h, 4 h and 24 h after i.v. 
injections are presented in Figure 1. LNC 25 nm disappeared quickly from the blood circulation: 3-
6% total CPM (counts per minute) / g of the 25 nm LNC was found in the blood at 1.5-4 h whereas 205 
the measured blood activities for LNC 50/100 nm were about 25-30 % at the same time points (p < 
0.001: LNC 25 nm vs. LNC 50/100 nm). Conversely, at 24 h, total CPM / g of LNC 25 nm was 
higher (~3%) than the corresponding LNC 50/100 nm values (~1.5%; p < 0.01). More activity of 
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LNC 25 nm was found in the liver at 1.5-4 h (~28%) compared to LNC 50 nm (16-18%; p < 0.01) 
and LNC 100 nm (21-22%; difference not significant). Also, compared to LNC 50/100 nm, more 210 
LNC 25 nm were found in the heart and in the lung (p < 0.01), and in the adrenal at 1.5-4 h. In 
contrast, at 24 h, less LNC 50 nm was found in the heart, lung and kidney compared to LNC 25/100 
nm (p < 0.05). The spleen captured less LNC 50 nm than LNC 25/100 nm at 1.5 h and 4 h (p < 
0.05). No significant differences were found in the tumour accumulation between the three particle 
sizes at different time points (1-3% total CPM / g). Otherwise, distribution in other organs was 215 
similar at different time points. 
 
γ-Scintigraphic images of mice 1.5 h, 3 h, 5 h, and 24 h after i.v. injection of 25, 50 and 100 nm 
99m
Tc-LNC are presented in Figure 2. The livers were well visible at 24 h. At earlier time points, 
especially at 1.5 h and 3 h, more vertical highlighted regions revealed also radioactivity in the blood 220 
circulation (heart, lungs). LNC 25 nm were better observable than LNC 50/100 nm in peripheral 
regions and at intestinal area of mice at 3 h and 5 h. These observations were supported by the γ-
counting results: if the values “% CPM of all organs” were not corrected by the organ masses, 
radioactivity in the carcass after the injection of LNC 25 nm were 39% at 1.5 h and 37% at 4 h. 
Corresponding values for LNC 50 and 100 nm were 22% (p < 0.001 vs. LNC 25 nm) and 22% (p < 225 
0.001); 15% (p < 0.01) and 18% (p < 0.05) at 1.5 h and 4 h, respectively. Also, at 4 h, 7.5% of LNC 
25 nm were found in the intestine vs. 4.5% of LNC 50 nm and 3% of LNC 100 nm (both p < 0.01 
vs. LNC 25 nm). 
 
3.3 Comparison of in vivo biodistribution of co-injected 
99m
Tc-LNC and DiD-LNC 230 
 
An example of fluorescence images of a mouse 24 h after injection of a 50%-50% mixture of 50 nm 
DiD-LNC and 
99m
Tc-LNC is presented in Figure 3. Fluorescence staining allowed identifying of the 
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liver (A) and the tumour (B). LNC biodistribution in different organs at 24 h is presented in Figure 
4. To better compare the quantification by the two techniques (γ-counting and fluorescence 235 
imaging), the organ data were normalized by the detected radioactivity (% ID/g) and fluorescence 
intensity (RLU/pixel/20 ms) in the bone. As already observed when testing radiolabelled LNC of 
different sizes, the majority of radioactivity was found in the liver as well as in the adrenal, spleen, 
and kidneys (Fig. 4A). Instead, the observed fluorescence intensity was also highest in the liver, but 
the next highest fluorescent organs were the ovaries, adrenal, and skin. The global fluorescence 240 
intensity in the spleen was low, and moderate in the kidneys. Radioactivity in relation to other 
organs was clearly higher in the liver, adrenal, spleen, kidney, ovary, and lung. No such clear 
differences were observed in fluorescence intensities. An image of the organs (Fig. 4B), used for the 
quantification, reveals well the highly fluorescent organs. 
 245 
4 Discussion 
 
Generally, sub-100 nm nanoparticles are expected to circulate longer time in the blood compared to 
> 100 nm particles (Vonarbourg et al., 2006). However, in the size range of 10-100 nm, surface and 
even elasticity properties of nanoparticles as well as their mechanism of elimination have been 250 
shown to dictate pharmacokinetic and biodistribution profiles. Also, animal model (mouse/rat) is 
known to affect tissue distribution (Sun et al., 2005). For example, systemic clearance and volume 
of distribution of 60 nm PEGylated polyacrylate nanoparticles in mice were significantly lower 
when compared to 20 nm particles, leading to lower liver uptake (~15% ID/g at 48 h) of the larger 
60 nm particles (Yang et al., 2009). Similarly, 25 nm polymer micelles exhibited much shorter 255 
circulation half-lives than 60 nm micelles (2.2-fold decrease in the distribution phase t1/2) (Lee et 
al., 2010). More efficient clearance by hepatobiliary excretion of the smaller micelles was proposed 
as ~70% of the (mouse) liver fenestrations are narrower than 100 nm. The longest blood half-life of 
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10-100 nm PEGylated gold nanoparticles was achieved with ~60 nm particles by adjusting the size 
and PEG length (Perrault et al., 2009). On the other hand, mice plasma clearance rates (12% ID/mL 260 
plasma at 24 h), and the quantities in kidney (~4% ID/g), liver (10-16% ID/g) and in spleen (5-10% 
ID/g) were similar regardless of the polymer micelle size (30-100 nm) (Cabral et al., 2011). Several 
studies have proposed wider distribution, extravasation, of nanoparticles in different organs, the 
smaller the particle size was in the sub-100 nm range (De Jong et al., 2008; Hirn et al., 2011; 
Sonavane et al., 2008; Yang et al., 2009). Similarly to our results with 25, 50, and 100 nm LNC, 265 
shortened blood circulation time is frequently related to this wider biodistribution. Higher quantity 
of LNC 25 nm in the liver (1.5, 4 h) compared to LNC 50/100 nm in the current study indicated 
also faster hepatic accumulation. Radioactivity found in the kidneys can be explained by LNC 
accumulation. To undergo a complete renal clearance, the nanoparticle size should be less than 10 
nm (Choi et al., 2007). Instead, 75±25 nm PEGylated gold nanoparticles are reported to enter the 270 
fenestrated glomerular endothelia (80-100 nm pores) and accumulate in the kidney mesangium 
(Choi et al., 2011). Nanoparticle accumulation in the ovaries, clearly visible in the case of LNC 
(Fig. 4), is assumed to originate from fast growing and, thus, highly vascularized nature of the 
ovarian corpus luteum of mature female mice that leads to the EPR (enhanced permeability and 
retention) effect, described initially for tumours (Schädlich et al., 2012). 275 
 
In our previous study, after i.v. injection, signals of fluorescent-labelled LNC 25 nm in the skin and 
in the intestine were found to be more intense than the corresponding signals of LNC 50/100 nm 
(Hirsjärvi et al., 2013). Thus, the results of the current study confirmed these findings. Almost twice 
the radioactivity of LNC 25 nm in carcass compared to LNC 50/100 nm at 1.5-4 h indicated, 280 
indeed, that the smallest LNC were distributed rapidly to the peripheral capillaries and probably 
perfused further to tissues increasing the skin fluorescence. Higher LNC 25 nm quantities in the 
intestine suggested more pronounced hepato-biliary evacuation. Differences in the elimination rate 
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of the three LNC could not be, however, revealed when estimated injected doses were compared to 
CPM of all organs. For each LNC type, differences between the different time points remained 285 
within 10% and were not significantly different. 
 
Magnitude of the tumour accumulation of nanoparticles by the EPR effect together with a 
therapeutic effect (of an encapsulated drug) remains in general in the range of 3.5-12% (ID/g) (de 
Wolf et al., 2007; Kircheis et al., 2002; Kursa et al., 2002; Meng et al., 2011). Accumulation of 290 
LNC 25-100 nm in HEK293(β3) tumour was a bit lower (1-3%). It should be noted, however, that 
this subcutaneous model is an “EPR-weak” tumour having well-structured, neo-angiogenic 
vasculature with tight endothelial junctions (Jin et al., 2007; Razkin et al., 2006). 
 
γ-Imaging of dual-labelled (radio+fluorescence) PEGylated polyacrylate nanoparticles revealed 295 
radioactivity in the cardiac area at early observation time points (5 min – 4 h) followed by 
increasing activity in liver and spleen up to 48 h (Yang et al., 2009). Tumour was poorly observable 
by γ-imaging but, instead, optical imaging that enhanced subcutaneous signal compared to deep 
signals, showed clear fluorescence staining in tumour. Subcutaneous tumours were well visualized 
by strongly surface-weighted optical imaging. Therefore, as in our studies ((Hirsjärvi et al., 2013) 300 
and the current study), optical imaging offers better resolution imaging especially for superficial 
organs whereas γ-scintigraphy recapitulates the global biodistribution of radiolabelled compounds 
in both internal and superficial organs. 
 
To better compare the biodistribution of LNC measured by the two techniques, radioactivity and 305 
fluorescence intensity, the corresponding results were normalized by the value observed in the 
bone. The bone was selected because its radioactivity / fluorescence intensity level was observed to 
be settled in the middle of all analysed organs, allowing, thus, distinct representation of the data. In 
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order to quantify fluorescence intensity of dissected organs, graphical ROI estimation from images 
visualized by a fluorescent camera is commonly performed. (Goutayer et al., 2010; Kim et al., 310 
2010; Na et al., 2011; Sancey et al., 2009; Schädlich et al., 2011a; Schädlich et al., 2011b; Yang et 
al., 2007). Alternatively, homogenization of each dissected organ followed by determination of the 
fluorescence intensity on a microtiter plate can be done (He et al., 2010; Meng et al., 2011). The 
fluorescence intensity technique (ROI drawing and estimation), compared to γ-counting, 
underestimated the LNC proportion in all the red and the dark red organs such as RES organs (liver, 315 
lung, spleen), and the kidney and adrenal. These organs are characterized by high blood perfusion. 
Similarly to our findings, ex vivo quantification of fluorescence intensity underestimated the uptake 
of polymer micelles in the liver, spleen, kidney, and also in the heart (Yang et al., 2007). For this 
reason, relative fluorescence intensity in other organs was found to be emphasized. Because of the 
fluorescence quantification technique in this study, intensities of thin organs (i.e. skin) were also 320 
slightly highlighted. It should be noted that direct comparison of the two quantification techniques 
after normalization (Fig. 4) is not recommendable but, instead, this approach revealed well the 
relative differences between the organs within each technique. 
 
5 Conclusions 325 
 
Biodistribution studies of radiolabelled 
99m
Tc-LNC in nude mice with subcutaneous HEK293(β3) 
xenografts revealed that the majority of the smallest studied particles (25 nm) disappeared quickly 
from the blood circulation within 1.5 h after the intravenous injection due to wider tissue 
distribution and faster elimination. Instead, 50 and 100 nm LNC remained in the circulation at least 330 
up to 4 h. At 24 h, biodistribution profiles of the all LNC were similar. Tumour accumulation of 
LNC in this EPR-weak tumour was low regardless the size. When biodistribution profiles of co-
injected 50 nm fluorescent DiD-LNC and 
99m
Tc-LNC after animal sacrifice were compared, 
 15 
underestimating tendency of fluorescence detection of LNC accumulation in highly-capturing and 
perfused organs (liver, adrenal, spleen, kidney, lung) was clearly observed but fluorescence 335 
detection allowed visualization of the tumour area. In following studies, we will further concentrate 
on the comparison of the two imaging / biodistribution evaluation techniques with the help of dual-
labelled nanocarriers and different tumour models. 
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Figure captions 
Table 1. Compositions of LNC of different sizes. 
 
 Solutol® 
(mg) 
Lipoid® 
(mg) 
Labrafac® 
(mg) 
NaCl 
(mg) 
Water 
(mg) 
Concentration 
(mg/mL) 
LNC 25 nm 645 25 282 30 685 168 
LNC 50 nm 282 25 343 30 987 115 
LNC 100 nm 161 25 403 30 1048 104 
 515 
Table 2. Size and ζ-potential of 99mTc-LNC measured in physiological PBS. 
 
 Diameter (nm) PdI ζ-Potential (mV) 
LNC 25 nm 25±2 0.08 -3±1 
LNC 50 nm 51±1 0.03 -4±1 
LNC 100 nm 93±1 0.04 -6±1 
 
 20 
 
Figure 1. Biodistribution of 25, 50, and 100 nm 
99m
Tc-LNC in different organs 1.5 h, 4 h, and 24 h 520 
after intravenous injection. CPM = counts per minute 
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Figure 2. γ-Scintigraphic images expressing biodistribution of 25, 50, and 100 nm 99mTc-LNC in 525 
mice 1.5 h, 3 h, 5 h, and 24 h after intravenous injection. Arrows indicate the liver. 
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 530 
Figure 3. LNC biodistribution by optical imaging. Fluorescence images of a mouse 24 h after an i.v. 
injection of a 50%-50% mixture of 50 nm 
99m
Tc-LNC and 50 nm DiD-LNC. Mouse lying on its 
back (A, arrow indicates the liver) and belly (B, arrow indicates the tumour). 
 
A B 
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 535 
 
 
Figure 4. Comparison of the two detection techniques, radioactivity and fluorescence intensity, for 
quantification of organ distribution of the 50%-50% mixture (50 nm DiD-LNC and 
99m
Tc-LNC) 24 
h after injection (A). Example of the dissected organs visualized by a fluorescence camera (B). 540 
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